MK-3866

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Antibacterial AgentsHepatic InsufficiencyRenal Impairment

Phase 1

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

CompletedNCT03259087

Merck Sharp & Dohme LLCRenal Impairment

Start: 2017-09-01End: 2018-02-09Updated: 2019-04-19

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

TerminatedNCT03295266

Merck Sharp & Dohme LLCAntibacterial Agents, Hepatic Insufficiency

Start: 2017-12-19End: 2018-03-15Updated: 2019-11-13